Increased peroxisome proliferator‑activated receptor γ expression levels in visceral adipose tissue, and serum CCL2 and interleukin-6 levels during visceral adipose tissue accumulation

Yogarajah,Thaneswary; Bee,Yvonne-Tee   Get; Noordin,Rahmah; Yin,Khoo  Boon

doi:10.3892/mmr.2014.2686

Increased peroxisome proliferator‑activated receptor γ expression levels in visceral adipose tissue, and serum CCL2 and interleukin-6 levels during visceral adipose tissue accumulation

Authors:
- Thaneswary Yogarajah
- Yvonne-Tee Get Bee
- Rahmah Noordin
- Khoo Boon Yin
View Affiliations

Affiliations: Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, 11800 Penang, Malaysia, School of Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
Published online on: October 16, 2014 https://doi.org/10.3892/mmr.2014.2686
Pages: 515-520

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to determine the mRNA and protein expression levels of peroxisome proliferator‑activated receptors (PPARs) in visceral adipose tissue, as well as serum adipokine levels, in Sprague Dawley rats. The rats were fed either a normal (control rats) or excessive (experimental rats) intake of food for 8 or 16 weeks, then sacrificed, at which time visceral and subcutaneous adipose tissues, as well as blood samples, were collected. The mRNA and protein expression levels of PPARs in the visceral adipose tissues were determined using reverse transcription-polymerase chain reaction and Western blotting, respectively. In addition, the levels of adipokines in the serum samples were determined using commercial ELISA kits. The results revealed that at 8 weeks, the mass of subcutaneous adipose tissue was higher than that of the visceral adipose tissue in the experimental rats, but the reverse occurred at 16 weeks. Furthermore, at 16 weeks the experimental rats exhibited an upregulation of PPARγ mRNA and protein expression levels in the visceral adipose tissues, and significant increases in the serum levels of CCL2 and interleukin (IL)-6 were observed, compared with those measured at 8 weeks. In conclusion, this study demonstrated that the PPARγ expression level was likely correlated with serum levels of CCL2 and IL-6, molecules that may facilitate visceral adipose tissue accumulation. In addition, the levels of the two adipokines in the serum may be useful as surrogate biomarkers for the expression levels of PPARγ in accumulated visceral adipose tissues.

View Figures

View References

1	Balistreri CR, Caruso C and Candore G: The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010:8020782010. View Article : Google Scholar : PubMed/NCBI
2	Mårin P, Andersson B, Ottosson M, et al: The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism. 41:1242–1248. 1992.PubMed/NCBI
3	Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 21:697–738. 2000. View Article : Google Scholar : PubMed/NCBI
4	Pascot A, Lemieux S, Lemieux I, et al: Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care. 22:1471–1478. 1999. View Article : Google Scholar : PubMed/NCBI
5	Sharma AM and Staels B: Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 92:386–395. 2007. View Article : Google Scholar
6	Fusco R, Galgani M, Procaccini C, et al: Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer. 17:373–382. 2010. View Article : Google Scholar
7	Hlavna M, Kohut L, Lipkova J, et al: Relationship of resistin levels with endometrial cancer risk. Neoplasma. 58:124–128. 2011. View Article : Google Scholar : PubMed/NCBI
8	Masaki T and Yoshimatsu H: Obesity, adipokines and cancer. Transl Oncogenomics. 3:45–52. 2008.
9	Nyante SJ, Gammon MD, Kaufman JS, et al: Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes. Breast Cancer Res Treat. 129:593–606. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kim SH, Nagalingam A, Saxena NK, Singh SV and Sharma D: Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis. 32:359–367. 2011. View Article : Google Scholar
11	Carter JC and Church FC: Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Res. 2009:3453202009.
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
13	Priego T, Sánchez J, Picó C and Palou A: Sex-differential expression of metabolism-related genes in response to a high-fat diet. Obesity (Silver Spring). 16:819–826. 2008. View Article : Google Scholar : PubMed/NCBI
14	Nomaguchi K, Tanaka M, Misawa E, et al: Aloe vera phytosterols act as ligands for PPAR and improve the expression levels of PPAR target genes in the livers of mice with diet-induced obesity. Obes Res Clin Pract. 5:e169–e266. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kavanagh K, Jones KL, Sawyer J, et al: Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity (Silver Spring). 15:1675–1684. 2007. View Article : Google Scholar : PubMed/NCBI
16	Hamdy O, Porramatikul S and Al-Ozairi E: Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2:367–373. 2006. View Article : Google Scholar : PubMed/NCBI
17	Duffield JA, Vuocolo T, Tellam R, et al: Intrauterine growth restriction and the sex specific programming of leptin and peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA expression in visceral fat in the lamb. Pediatr Res. 66:59–65. 2009. View Article : Google Scholar
18	Dewulf EM, Cani PD, Neyrinck AM, et al: Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem. 22:712–722. 2011. View Article : Google Scholar : PubMed/NCBI
19	Arai K, Soga T, Ohata H, Otagiri A and Shibasaki T: Effects of food restriction on peroxisome proliferator-activated receptor-gamma and glucocorticoid receptor signaling in adipose tissues of normal rats. Metabolism. 53:28–36. 2004. View Article : Google Scholar : PubMed/NCBI
20	Barak Y and Kim S: Genetic manipulations of PPARs: effects on obesity and metabolic disease. PPAR Res. 2007:127812007. View Article : Google Scholar : PubMed/NCBI
21	Nicholas SB, Kawano Y, Wakino S, Collins AR and Hsueh WA: Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension. 37:722–727. 2001. View Article : Google Scholar : PubMed/NCBI
22	Larsen TM, Toubro S and Astrup A: PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord. 27:147–161. 2003. View Article : Google Scholar : PubMed/NCBI
23	Lehrke M and Lazar MA: The many faces of PPARgamma. Cell. 123:993–999. 2005. View Article : Google Scholar : PubMed/NCBI
24	Frühbeck G and Salvador J: Role of adipocytokines in metabolism and disease. Nutr Res. 24:803–826. 2004.
25	Tontonoz P and Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 77:289–312. 2008. View Article : Google Scholar : PubMed/NCBI
26	Malavazos AE, Cereda E, Morricone L, et al: Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. Eur J Endocrinol. 153:871–877. 2005. View Article : Google Scholar
27	Huber J, Kiefer FW, Zeyda M, et al: CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab. 93:3215–3221. 2008. View Article : Google Scholar : PubMed/NCBI
28	Chen A, Mumick S, Zhang C, et al: Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res. 13:1311–1320. 2005. View Article : Google Scholar : PubMed/NCBI
29	Park HS, Park JY and Yu R: Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 69:29–35. 2005. View Article : Google Scholar : PubMed/NCBI
30	Monti P, Leone BE, Marchesi F, et al: The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 63:7451–7461. 2003.PubMed/NCBI
31	Ueno T, Toi M, et al: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 6:3282–3289. 2000.PubMed/NCBI
32	Saji H, Koike M, Yamori T, et al: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 92:1085–1091. 2001. View Article : Google Scholar : PubMed/NCBI
33	Ohta M, Kitadai Y, Tanaka S, et al: Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol. 22:773–778. 2003.